Protocol Ledger

NCT05844150 · Phase II · ACTIVE NOT RECRUITING

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Interventional Phase II clinical trial protocol NCT05844150 sponsored by Biotheus in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-01 Enrollment: 50 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05844150
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05844150
Protocol FieldVerified Registry Value
NCT IdentifierNCT05844150
Consolidated Lead SponsorBiotheus
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment50 participants (ACTUAL)
Registered Start Date2023-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI